0001209191-17-034073.txt : 20170519 0001209191-17-034073.hdr.sgml : 20170519 20170519185616 ACCESSION NUMBER: 0001209191-17-034073 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170516 FILED AS OF DATE: 20170519 DATE AS OF CHANGE: 20170519 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: G1 Therapeutics, Inc. CENTRAL INDEX KEY: 0001560241 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263648180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 79 T.W. ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-213-9835 MAIL ADDRESS: STREET 1: P. O. BOX # 110341 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: G-Zero Therapeutics, Inc. DATE OF NAME CHANGE: 20121012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RUDNICK SETH CENTRAL INDEX KEY: 0001184420 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38096 FILM NUMBER: 17859419 MAIL ADDRESS: STREET 1: 7100 WEST CREDIT AVENUE, SUITE 101 STREET 2: C/O ARALEZ PHARMACEUTICALS CITY: MISSISSAUGA STATE: A6 ZIP: L5N 0E4 3/A 1 doc3a.xml FORM 3/A SUBMISSION X0206 3/A 2017-05-16 2017-05-16 0 0001560241 G1 Therapeutics, Inc. GTHX 0001184420 RUDNICK SETH C/O G1 THERAPEUTICS, INC. 79 T.W. ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 1 0 0 0 Stock Option (Right to Buy) 0.30 2025-02-27 Common Stock 13890 D The shares underlying this option vested as to 25% of the shares on February 28, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. A portion this stock option was exercised exercised prior to the date of the original filing. The number of underlying shares of common stock and the exercise price reported reflect a 1-for-3 reverse stock split of the Issuer's common stock effected on May 11, 2017. This amendment is being filed to correct the number of shares underlying the stock option. The original filing on May 16, 2017 noted that the number of shares underlying the stock option was 83,333. The correct number is 13,890. /s/ Caroline G. Gammill, attorney-in-fact 2017-05-19